MDXG250117P7500
- 0.00
- 0.000.00%
MiMedx Newsroom
MiMedx (MDXG) Is on the Move, Here's Why the Trend Could Be Sustainable
What MiMedx Group, Inc.'s (NASDAQ:MDXG) 27% Share Price Gain Is Not Telling You
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
MiMedx Group (NASDAQ:MDXG) Rises 4.6% This Week, Taking Three-year Gains to 39%
Institutional Investors Own a Significant Stake of 43% in MiMedx Group, Inc. (NASDAQ:MDXG)
Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)
Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?
A Quick Look at Today's Ratings for MiMedx(MDXG.US), With a Forecast Between $12 to $16
Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
Express News | MiMedx Group Inc : Mizuho Raises Target Price to $16 From $14
MiMedx Group Provides Update On Local Coverage Determinations; Raises Separate Treatment Applications A Patient Can Receive From 4 To 8; Increased Treatment Duration From 12 To 16 Weeks
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results With Planned Implementation of LCDs
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
MIMEDX to Participate in Upcoming Investor Conferences
A Quick Look at Today's Ratings for MiMedx(MDXG.US), With a Forecast Between $11 to $12
Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness
MiMedx Group Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
12 Health Care Stocks Moving In Thursday's Intraday Session